TOP TEN perturbations for 38411_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38411_at
Selected probe(set): 203509_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38411_at (203509_at) across 6674 perturbations tested by GENEVESTIGATOR:
VTX-2337 study 1 / untreated monocyte sample
Relative Expression (log2-ratio):-5.084098Number of Samples:3 / 3
| Experimental | VTX-2337 study 1 |
| Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM VTX-2337 drug, which represents a TLR8 (Toll-like receptor 8) agonist with potential immunostimulating and antineoplastic activities. | |
| Control | untreated monocyte sample |
| Peripheral blood monocytes isolated from healthy donors. |
VTX-2337 study 1 / 3M-055 study 1
Relative Expression (log2-ratio):-4.8913918Number of Samples:3 / 3
| Experimental | VTX-2337 study 1 |
| Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM VTX-2337 drug, which represents a TLR8 (Toll-like receptor 8) agonist with potential immunostimulating and antineoplastic activities. | |
| Control | 3M-055 study 1 |
| Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM 3M-055 drug, which represents a TLR7 (Toll-like receptor 7) agonist. |
pancreatic islet study 3 (re-differentiated; PPRF; 4d) / normal pancreatic islet sample
Relative Expression (log2-ratio):-4.402317Number of Samples:2 / 7
| Experimental | pancreatic islet study 3 (re-differentiated; PPRF; 4d) |
| Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded for 6 weeks and re-differentiated for 4 days according to Pharmaceutical Production Research Facility (PPRF) Protocol. Re-differentiation phase: For induction of expanded cells to differentiate into islet-like cell clusters, the cells were seeded into 60 mm ultra-low attachment dishes in serum-free CMRL-1066 supplemented with 4 mM L-glutamine, 1% BSA, insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml), and 1% antibiotic antimycotic solution at a density of 6.0 x 10EXP6 cells per dish. The induction medium was further added with islet neogenesis-associated protein (INGAP) peptide at a concentration of 1.0ug/ml. | |
| Control | normal pancreatic islet sample |
| Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation. |
pancreatic islet study 3 (expanded; PPRF) / normal pancreatic islet sample
Relative Expression (log2-ratio):-4.3862133Number of Samples:2 / 7
| Experimental | pancreatic islet study 3 (expanded; PPRF) |
| Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded according to Pharmaceutical Production Research Facility Protocol (PPRF) for 6 weeks. Expansion phase: Approximately 2,500 islet equivalents were seeded onto 75-cm2 fibronectin-coated tissue culture-treated flasks in a proprietary serum-free medium (PPRF medium). The serum-free PPRF medium was supplemented with 30% serum-free mesenchymal-conditioned medium. When the cell migration resulted in the formation of large-size colonies, the cells were harvested by trypsinization and replated into new tissue culture flasks. Once the cells reached near confluence (80–90%) in monolayer, they were trypsinized, counted, and subcultured at a density of 5,000 cells per cm2. Thereafter, cells were serially passaged using the same protocol. | |
| Control | normal pancreatic islet sample |
| Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation. |
pancreatic islet study 3 (re-differentiated; PPRF; 6d) / normal pancreatic islet sample
Relative Expression (log2-ratio):-4.2727795Number of Samples:2 / 7
| Experimental | pancreatic islet study 3 (re-differentiated; PPRF; 6d) |
| Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded for 6 weeks and re-differentiated for 6 days according to Pharmaceutical Production Research Facility (PPRF) Protocol. Re-differentiation phase: For induction of expanded cells to differentiate into islet-like cell clusters, the cells were seeded into 60 mm ultra-low attachment dishes in serum-free CMRL-1066 supplemented with 4 mM L-glutamine, 1% BSA, insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml), and 1% antibiotic antimycotic solution at a density of 6.0 x 10EXP6 cells per dish. The induction medium was further added with islet neogenesis-associated protein (INGAP) peptide at a concentration of 1.0 ug/ml. | |
| Control | normal pancreatic islet sample |
| Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation. |
pancreatic islet study 3 (re-differentiated; PPRF; 8d) / normal pancreatic islet sample
Relative Expression (log2-ratio):-4.2306366Number of Samples:2 / 7
| Experimental | pancreatic islet study 3 (re-differentiated; PPRF; 8d) |
| Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded for 6 weeks and re-differentiated for 8 days according to Pharmaceutical Production Research Facility (PPRF) Protocol. Re-differentiation phase: For induction of expanded cells to differentiate into islet-like cell clusters, the cells were seeded into 60 mm ultra-low attachment dishes in serum-free CMRL-1066 supplemented with 4 mM L-glutamine, 1% BSA, insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml), and 1% antibiotic antimycotic solution at a density of 6.0 x 10EXP6 cells per dish. The induction medium was further added with islet neogenesis-associated protein (INGAP) peptide at a concentration of 1.0 ug/ml. | |
| Control | normal pancreatic islet sample |
| Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation. |
lung cancer study 1 (PDX; large cell carcinoma, NOS; primary) / lung cancer study 1 (PDX; basaloid carcinoma; primary)
Relative Expression (log2-ratio):-4.2062626Number of Samples:4 / 3
| Experimental | lung cancer study 1 (PDX; large cell carcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary large cell carcinoma, NOS of the lung (subcutaneously implanted). | |
| Control | lung cancer study 1 (PDX; basaloid carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary basaloid carcinoma of the lung (subcutaneously implanted). |
pancreatic islet study 3 (re-differentiated; PPRF; 2d) / normal pancreatic islet sample
Relative Expression (log2-ratio):-4.1576214Number of Samples:2 / 7
| Experimental | pancreatic islet study 3 (re-differentiated; PPRF; 2d) |
| Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded for 6 weeks and re-differentiated for 2 days according to Pharmaceutical Production Research Facility (PPRF) Protocol. Re-differentiation phase: For induction of expanded cells to differentiate into islet-like cell clusters, the cells were seeded into 60 mm ultra-low attachment dishes in serum-free CMRL-1066 supplemented with 4 mM L-glutamine, 1% BSA, insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml), and 1% antibiotic antimycotic solution at a density of 6.0 x 10EXP6 cells per dish. The induction medium was further added with islet neogenesis-associated protein (INGAP) peptide at a concentration of 1.0ug/ml. | |
| Control | normal pancreatic islet sample |
| Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation. |
IFN-g; LPS study 1 / normal resting monocyte sample
Relative Expression (log2-ratio):-4.1284676Number of Samples:2 / 2
| Experimental | IFN-g; LPS study 1 |
| Monocytes LPS/IFN-g activated for 30h. | |
| Control | normal resting monocyte sample |
| Monocytes resting for 30h. |
memory B cell study 1 (CD27high) / memory B cell study 1 (undivided)
Relative Expression (log2-ratio):-4.0090246Number of Samples:6 / 6
| Experimental | memory B cell study 1 (CD27high) |
| CD27 enriched proliferating human memory B cells expressing high level of CD27 (marker of antibody secretion) activated with CpG oligodeoxynucleotide (10 ng/ml), recombinant human cytokines IL-2 (20 IU/ml), IL-10 (50 ng/ml), IL-15 (10 ng/ml), recombinant human BAFF (75 ng/ml) in PC-L medium (IMDM medium, lacromin (50mg/ml), insulin (5mg/ml), penicillin/streptomycin, gentamicin (15mg/ml), normocin (0.1% v/v), 10% FCS) for 80 hours. | |
| Control | memory B cell study 1 (undivided) |
| CD27 enriched undivided human memory B cells (expressing low level of CD27) activated with CpG oligodeoxynucleotide (10 ng/ml), recombinant human cytokines IL-2 (20 IU/ml), IL-10 (50 ng/ml), IL-15 (10 ng/ml), recombinant human BAFF (75 ng/ml) in PC-L medium (IMDM medium, lacromin (50mg/ml), insulin (5mg/ml), penicillin/streptomycin, gentamicin (15mg/ml), normocin (0.1% v/v), 10% FCS) for 80 hours. |